MedTrace Logo

Lofexidine for Opiate Withdrawal - 1

NCT00032942 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2017-01-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate lofexidine for opiate withdrawal.

Conditions

  • Opioid-Related Disorders

Interventions

DRUG

Lofexidine

Sponsors & Collaborators

  • Britannia Pharmaceuticals Ltd.

    collaborator INDUSTRY

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Principal Investigators

  • Ann Montgomery, R.N. · National Institute on Drug Abuse (NIDA)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-04-30
Primary Completion
2004-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00032942 on ClinicalTrials.gov